NCT02309424 is a NA clinical trial of Vinegar in Type 2 Diabetes, sponsored by Attikon Hospital.

Who is sponsoring NCT02309424?

NCT02309424 is sponsored by Attikon Hospital.

What drugs are being tested in NCT02309424?

Interventions in NCT02309424: Vinegar, Placebo.

What condition does NCT02309424 study?

NCT02309424 studies Type 2 Diabetes.

Is NCT02309424 still recruiting?

NCT02309424 is currently completed. Last updated 4 December 2014.

Last reviewed 2014-12-04 · How we verify

NCT02309424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Vinegar on Glucose and Lipid Metabolism in Peripheral Tissues in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes

Completed NA Last updated 4 December 2014

What this trial tests

NA trial testing Vinegar in Type 2 Diabetes in 20 participants. Completed in 1 December 2014.

Timeline

1 July 2008

Primary endpoint
1 December 2013

1 December 2014

Quick facts

Lead sponsor	Attikon Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Enrollment	20
Start date	1 July 2008
Primary completion	1 December 2013
Estimated completion	1 December 2014

Drugs / interventions tested

Vinegar
Placebo

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Attikon Hospital

Who can join

Adults 18 to 65, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Muscle glucose uptake following meal ingestion (area under the glucose uptake versus time curve-AUC)
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal

Sponsor's own description

This open, randomized, cross-over, placebo-controlled study aims to investigate the effects of vinegar on glucose metabolism, endothelial function and circulating lipid levels in subjects with impaired glucose tolerance or type 2 diabetes, using the arteriovenous difference technique.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Vinegar Consumption Increases Insulin-Stimulated Glucose Uptake by the Forearm Muscle in Humans with Type 2 Diabetes.
Mitrou P, Petsiou E, Papakonstantinou E, Papakonstantinou E, et al · · 2015 · cited 22× · PMID 26064976 · DOI 10.1155/2015/175204
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.
Williams LM, Cao S. · · 2024 · cited 13× · PMID 38367866 · DOI 10.1016/j.pharmthera.2024.108605

Verify or expand the search:

Other trials of Vinegar

Trials testing the same drug.

NCT04120259 — Effect of Apple Cider Vinegar and Metformin Combination vs Metformin Alone in Type 2 Diabetics · NA · completed

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Attikon Hospital trials

Trials by the same sponsor.

NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
NCT06810700 — The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function · not yet recruiting
NCT06978387 — The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes. · active not recruiting
NCT06749613 — Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02309424 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Attikon Hospital
Last refreshed: 4 December 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02309424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing